Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|122|17|2680-2688

ISSN： 0008-543x

Source： CANCER, Vol.122, Iss.17, 2016-09, pp. : 2680-2688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relapse after High-Dose Therapy in Relapsed Ewing’s Tumor Patients: Effects of Maintenance Chemotherapy in Two Selected Patients?

By  

Oncology Research and Treatment, Vol. 26, Iss. 6, 2004-01 ,pp. : 573-577

Karger

Access to resources Recommend Favorite

High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 257-261

Karger

Access to resources Recommend Favorite

First-Line High-Dose Chemotherapy for ’Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors

By  

Oncology Research and Treatment, Vol. 21, Iss. 2, 1998-06 ,pp. : 23-25

Karger

Access to resources Recommend Favorite

A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 902-904

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite